Valneva SE (VALN)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form EFFECT - Notice of Effectiveness

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Elaris Secures Exclusive Global License from Valneva for C. difficile Vaccine Program

Elaris Secures Exclusive Global License from Valneva for C. difficile Vaccine Program PR Newswire VIENNA...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Valneva shares slide after U.S. pullback on chikungunya vaccine filing

Valneva SE ADR (NASDAQ:VALN) shares dropped 6.6% in premarket trading on Tuesday after the vaccine maker said it has voluntarily withdrawn both...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Valneva Shares Rise on Strong Booster Results for Lyme Disease Vaccine Candidate

Valneva SE (NASDAQ:VALN) saw its stock move higher on Wednesday after the company released final Phase II results for its Lyme disease vaccine...